Table 3.
Results of overall and stratified analyses for the association of XRCC1 399 G → A and risk of glioma, Yosunkaya et al.[34]excluded
| Stratification factor | No. of studies | I2(%) | Odds ratio | 95% Confidence interval | P value |
|---|---|---|---|---|---|
| Overall |
5 |
7 |
1.10 |
0.98-1.23 |
0.10 |
| Gender | |||||
| Male |
1 |
NA |
0.94 |
0.62-1.44 |
0.78 |
| Female |
1 |
NA |
2.27 |
1.45-3.57 |
< 0.001 |
| Glioma Subtype | |||||
| Grade III |
2 |
0 |
1.05 |
0.89-1.25 |
0.56 |
| Grade IV |
2 |
46 |
1.20 |
0.97-1.47 |
0.09 |
| Sample size | |||||
| < 500 |
1 |
NA |
1.61 |
0.93-2.78 |
0.09 |
| ≥ 500 |
4 |
0 |
1.08 |
0.96-1.21 |
0.19 |
| Country | |||||
| US |
3 |
8 |
1.11 |
0.94-1.31 |
0.22 |
| Other |
2 |
53 |
1.09 |
0.94-1.27 |
0.26 |
| Genotyping method | |||||
| PCR-RFLP |
3 |
27 |
1.06 |
0.93-1.21 |
0.40 |
| Other | 2 | 0 | 1.19 | 0.97-1.46 | 0.09 |